This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
The University of Pennsylvania and Roche’s Genentech unit have settled a lawsuit...
CMI Media Group’s Centered social enterprise ties social content and influencer ...
For the last year, AstraZeneca has been urging sports fans to “Get Body Checked ...
Several months after a group of senators sent letters to Pfizer and Eli Lilly in...
The FDA chief counsel pick quickly attracted controversy due to her prior defens...
Under one of two policy tools that the U.K. uses to control drug costs, the Brit...
In a year in which he faced down a challenge from activist investor Starboard Va...
Following a fire at a Bayer executive’s home earlier this month, eight agencies—...
Following a fire at a Bayer executive’s home earlier this month, eight agencies—...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
This week on "The Top Line," we dissect the unprecedented revenue growth enjoyed...
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acqu...
AstraZeneca is hopping aboard the pickleball craze as its serves up a new market...
Following a hard-fought yet limited FDA approval last year, Akebia plans to kick...
In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simul...
Having spent the better part of the decade grappling with bankruptcy bids and op...
Novartis has teamed up with the NFL in a multi-year partnership, marking the fir...
Niemann-Pick disease type C therapy Miplyffa became commercially available in la...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
While Stéphane Bancel received a lower-than-targeted bonus on the back of declin...
Treatments for autoimmune diseases and those in orphan markets are on the up and...
On track to meet their long-stated capacity goal for multiple myeloma therapy Ca...
Treatments for autoimmune diseases and those in orphan markets are on the up and...